What are Mission Vision & Core Values of Shin Nippon Biomedical Laboratories Company?

What are the Mission, Vision, and Core Values of Shin Nippon Biomedical Laboratories?

Mission and vision statements are crucial strategic foundations for any business, offering a clear sense of purpose and direction. These statements articulate an organization's ultimate goals and the path to achieve them, guiding business decisions and shaping corporate identity. Shin Nippon Biomedical Laboratories (SNBL) holds a significant position in the global contract research organization (CRO) industry.

As a leading provider of preclinical and clinical development services, including non-human primate studies, SNBL accelerates new therapies from research to market. Their mission, vision, and values are instrumental in guiding strategic choices, influencing operational practices, and defining their unique contribution to advancing drug discovery and medical technology. For more insights, explore the Shin Nippon Biomedical Laboratories BCG Matrix.

The Shin Nippon Biomedical Laboratories mission statement emphasizes its dedication to advancing drug discovery and medical technology. This commitment aims to alleviate human suffering globally. SNBL's services, including preclinical and clinical development, directly contribute to bringing new therapies to market.

Advancing Drug Discovery

SNBL supports pharmaceutical and biotechnology companies in developing new drugs. This includes comprehensive preclinical and clinical services.

Medical Technology Support

The company aids in the advancement of medical technologies. This ensures innovative solutions reach patients faster.

Alleviating Suffering

A core aspect of the SNBL mission is to free humanity from suffering. This is achieved through effective and safe medical interventions.

Global Market Reach

SNBL operates globally, serving clients worldwide. This broad reach maximizes its impact on public health.

Customer-Centric Approach

The company focuses on client needs, supporting pharmaceutical and biotech firms. This ensures successful drug development.

Innovation Focus

SNBL is committed to innovation in drug discovery and medical technology. This drives continuous improvement and new solutions.

The Shin Nippon Biomedical Laboratories mission is to support the advancement of drug discovery and medical technology, aiming to liberate humanity from suffering. This commitment is evident in their global operations, serving pharmaceutical and biotechnology companies with comprehensive preclinical and clinical development services. For more details on the company's background, read this Brief History of Shin Nippon Biomedical Laboratories. SNBL's unique value proposition lies in accelerating new therapies to market, directly contributing to patient well-being. For instance, the U.S. FDA approval of Atzumi™ (dihydroergotamine) nasal powder in May 2025, for acute migraine treatment, showcases their direct impact. Furthermore, their ongoing Phase 2 clinical trials for brincidofovir (BCV) for adenovirus infections, with a Phase III application submitted to the European Medicines Agency (EMA) in June 2025, highlights their dedication to addressing human suffering through innovative drug development. The SNBL mission statement underscores a patient-centric approach, aligning their business objectives with global health needs.

Complete Shin Nippon Biomedical Laboratories Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

The Shin Nippon Biomedical Laboratories vision statement, 'Creating a Chain of Happiness by Being Close to Stakeholders,' guides its strategic direction towards 2028. This vision emphasizes fostering happiness through close collaboration with diverse stakeholders, extending beyond market leadership to integrate economic and social value. The company's continuous growth and strategic investments support this ambitious outlook.

Strategic Growth

Shin Nippon Biomedical Laboratories achieved record-high revenue for the third consecutive year in FY2025.

Nonclinical Business Expansion

Contracts received in the nonclinical business increased by 17.1% year-over-year to ¥32.1 billion in FY2025.

Investment Peak

Strategic up-front investments in facility expansion and a domestic non-human primate breeding system are peaking in FY2025.

Return on Investment

These investments are projected to enter a return on investment phase from FY2026 onwards.

Projected Contract Increase

Nonclinical business contracts are projected to increase by 9.6% year-over-year to ¥35.2 billion in FY2026.

Global Demand

Strong demand from clients in the U.S. and Europe is driving the projected growth in nonclinical business.

SNBL's 2028 Vision, 'Creating a Chain of Happiness by Being Close to Stakeholders,' is distinctly future-oriented and broadly scoped, aiming for a significant global impact by fostering happiness through close collaboration with its diverse stakeholders. This vision extends beyond mere market leadership, emphasizing integrated economic and social value creation. The vision appears aspirational yet realistic, especially given the company's continuous growth and strategic investments. For instance, SNBL achieved record-high revenue for the third consecutive year in FY2025, with contracts received in the nonclinical business increasing by 17.1% year-over-year to ¥32.1 billion. The company is also making strategic up-front investments in facility expansion and establishing a domestic non-human primate (NHP) breeding system, with these investments planned to peak in FY2025 and enter a return on investment phase from FY2026 onwards. These investments, alongside a projected 9.6% year-over-year increase in nonclinical business contracts to ¥35.2 billion in FY2026, driven by strong demand from clients in the U.S. and Europe, indicate a trajectory consistent with their ambitious Shin Nippon Biomedical Laboratories vision. For more details on the company's foundational principles, refer to the article on Mission, Vision & Core Values of Shin Nippon Biomedical Laboratories.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Shin Nippon Biomedical Laboratories core values are fundamental to its operations, guiding its strategic decisions and corporate culture. These values, deeply embedded in the company's philosophy, shape its approach to research, development, and stakeholder engagement. The company's four core values are Environment, Life, Human Resources, and Customer Satisfaction.

Environment (Blue)

The 'Environment' value, represented by blue, signifies SNBL's commitment to preserving the planet. This includes proactive measures to reduce greenhouse gas emissions, aiming for carbon neutrality in Scope 1 and Scope 2 emissions from their domestic business activities by FY2030. SNBL also supports the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) and discloses information on climate change impacts.

Life (Green)

The 'Life' value, symbolized by green, represents reverence for irreplaceable and precious life. In product development, this translates into rigorous safety assessment and ethical considerations, particularly in their non-human primate studies, ensuring the well-being of the animals used in research to advance human health. This commitment drives the urgency to accelerate drug development that liberates humanity from suffering, aligning with SNBL's patient care principles.

Human Resources (Navy Blue)

'Human Resources,' represented by navy blue, emphasizes valuing the 'heart' necessary for individuals to truly be assets to society and the company. This manifests in corporate culture through initiatives like introducing a new work style system to build 'a company where everybody works happily' and promoting businesses based on the concept of 'encouraging employees' growth'. SNBL actively invests in human capital development, including hiring 96 new graduates in April 2024 and actively implementing mid-career hiring, reflecting SNBL's employee development values.

Customer Satisfaction

Customer satisfaction is a paramount core value, ensuring that all services and products meet the highest quality standards. This commitment is evident in SNBL's dedication to providing tailored solutions and leveraging the expertise of its diverse workforce to meet client needs effectively. For more insights into how SNBL addresses its clientele, explore the Target Market of Shin Nippon Biomedical Laboratories.

These core values of Shin Nippon Biomedical Laboratories underpin its strategic goals and organizational culture. Understanding how these values influence the company's strategic decisions is crucial for grasping its long-term strategy and business objectives.

Shin Nippon Biomedical Laboratories Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

A company's mission and vision are foundational, shaping its strategic decisions and guiding its path forward. They articulate the organization's purpose and its aspirations for the future.

Shin Nippon Biomedical Laboratories' Guiding Principles

Shin Nippon Biomedical Laboratories (SNBL) integrates its mission and vision into its core business strategy, directly influencing its long-term planning and operational decisions.

• The mission to 'support the advancement of drug discovery and medical technology, and to liberate humanity from suffering' is the bedrock of its CRO and Translational Research (TR) businesses.
• SNBL's 2028 Vision of 'Creating a Chain of Happiness by Being Close to Stakeholders' guides its market expansion and partnership strategies.
• The company's corporate principle is to be 'committed to the environment, life, and people,' driving its unique business model.
• SNBL's strategic goals are deeply intertwined with its mission to accelerate drug development and enhance patient well-being.

Mission in Action: Advancing Medical Technology

SNBL's mission to advance medical technology is exemplified by its strategic acquisition of Satsuma Pharmaceuticals, which led to the U.S. FDA approval of Atzumi™ (dihydroergotamine) nasal powder in May 2025. This product utilizes SNBL's proprietary nasal drug delivery platform, directly aligning with its purpose of bringing innovative therapies to market.

Vision in Practice: Global Partnerships and Innovation

The vision to create a 'Chain of Happiness' influences SNBL's global reach. The establishment of a joint venture with Tasso in Japan in March 2025 for blood collection devices and the November 2024 partnership with SBI Holdings and Plug and Play for business incubation in the U.S. demonstrate this commitment to expanding access and fostering innovation.

Measurable Success: Financial Growth and Operational Focus

SNBL achieved record-high revenue for the third consecutive year in FY2025. Contracts in the nonclinical business grew by 17.1% year-over-year to ¥32.1 billion, and equity method profit from PPD-SNBL reached a record ¥3.2 billion, reflecting the success of its mission-aligned strategies.

Human Capital: Employee Well-being and Growth

The company's commitment to its people is evident in its human capital management, including the introduction of a new work style system designed to promote employee happiness and growth, further shaping its organizational culture and long-term planning.

Core Values: Ethical Foundation

SNBL's core values are rooted in a commitment to the environment, life, and people, forming the ethical guidelines that underpin its operations and its focus on life science and drug development.

Strategic Alignment: Driving Business Objectives

The company's mission and vision directly drive its business objectives, ensuring that strategic decisions, such as market expansion and technological investment, are consistently aligned with its overarching purpose and long-term aspirations. Understanding these principles is key to analyzing the Competitors Landscape of Shin Nippon Biomedical Laboratories.

SNBL's mission and vision are integral to its strategic decision-making, guiding its pursuit of innovation and its commitment to improving human health. Explore core improvements to company's mission and vision in the next chapter.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE

Shin Nippon Biomedical Laboratories' mission, vision, and core values provide a strong foundation for its operations. Enhancing these statements can further solidify its market position and future growth trajectory.

Here are four key areas for improvement:

Explicitly Integrate Diversity, Equity, and Inclusion (DEI)

While Shin Nippon Biomedical Laboratories' core values encompass 'human resources,' explicitly integrating DEI principles would align with modern best practices and broaden its appeal to a diverse talent pool and stakeholder base.

Emphasize Digital Transformation and Advanced Technology Adoption

Formally incorporating 'digital transformation' and 'advanced technology adoption' into the vision would underscore the company's commitment to leveraging technology for efficiency and innovation, especially as the CRO market sees significant disruption from AI, potentially impacting 40% of its current value.

Broaden Sustainability Commitments Beyond Environmental Focus

Expanding the emphasis on 'sustainability' beyond environmental aspects to include supply chains and resource management would address growing ESG concerns, enhancing appeal to stakeholders in a market where preclinical CROs are projected to reach USD 13.14 billion by 2034.

Reinforce Commitment to Innovation and Research Focus

Further highlighting the commitment to innovation and research focus within the mission and vision statements would clearly articulate the company's strategic direction and its role in advancing biomedical science, aligning with its ongoing DX project for automation and robotization.